Nexalin Technology, Inc.

NasdaqCM NXL

Nexalin Technology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -3,427.10%

Nexalin Technology, Inc. Net Income Margin is -3,427.10% for the Trailing 12 Months (TTM) ending September 30, 2024, a 3.78% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Nexalin Technology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -3,561.59%, a -2,852.68% change year over year.
Nexalin Technology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -120.62%, a 96.90% change year over year.
Nexalin Technology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -3,892.90%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: NXL

Nexalin Technology, Inc.

CEO	Mr. Mark White
IPO Date	Sept. 16, 2022
Location	United States
Headquarters	1776 Yorktown
Employees	6
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

Key trends

Past 5 years